{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:52:54Z","timestamp":1768773174698,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973188"],"award-info":[{"award-number":["81973188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["CPU2018GF02"],"award-info":[{"award-number":["CPU2018GF02"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115833","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T17:18:18Z","timestamp":1695662298000},"page":"115833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma"],"prefix":"10.1016","volume":"261","author":[{"given":"Linfu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengzhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6699-9617","authenticated-orcid":false,"given":"Qing-Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib1","first-page":"1155","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"23","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115833_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115833_bib4","first-page":"5355","article-title":"Targeting histone deacetylases in malignant melanoma: a future therapeutic agent or just great expectations?","volume":"37","author":"Garmpis","year":"2017","journal-title":"Anticancer Res."},{"issue":"28","key":"10.1016\/j.ejmech.2023.115833_bib5","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2174\/1568026619666181210152115","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"18","author":"Sun","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115833_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","article-title":"TRAIL on trial: preclinical advances in cancer therapy","volume":"19","author":"Stuckey","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115833_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/SAP.0000000000001066","article-title":"Histone deacetylase inhibitors enhance cytotoxicity towards breast tumors while preserving the wound-healing function of adipose-derived stem cells","volume":"78","author":"Koko","year":"2017","journal-title":"Ann. Plast. Surg."},{"key":"10.1016\/j.ejmech.2023.115833_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114049","article-title":"Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of DLBCL by improving metabolic stability and pharmacokinetic characteristics","volume":"229","author":"Cui","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115833_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115833_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/14756366.2022.2063281","article-title":"Phosphorus containing analogues of SAHA as inhibitors of HDACs","volume":"37","author":"Pun","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115833_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/tomography8020057","article-title":"Final report on clinical outcomes and tumor recurrence patterns of a pilot study assessing efficacy of belinostat (PXD-101) with chemoradiation for newly diagnosed glioblastoma","volume":"8","author":"Xu","year":"2022","journal-title":"tomography"},{"issue":"24","key":"10.1016\/j.ejmech.2023.115833_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415671","article-title":"The combination of panobinostat and melphalan for the treatment of patients with multiple myeloma","volume":"23","author":"Gkotzamanidou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115833_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-022-04425-3","article-title":"PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma","volume":"89","author":"Robinson","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115833_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270854","article-title":"Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort","volume":"17","author":"Maouche","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115833_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41401-021-00817-y","article-title":"FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11","volume":"43","author":"Yin","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115833_bib16","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.13315","article-title":"Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death","volume":"169","author":"Mishima","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115833_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up","volume":"162","author":"Tsai","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115833_bib20","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib22","first-page":"1446","article-title":"Low-dose tubacin promotes BMSCs proliferation and morphological changes through the ERK pathway","volume":"11","author":"Liang","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejmech.2023.115833_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainresbull.2020.06.010","article-title":"Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of \u03b1-phenyl tropolone, HPOB, and sodium valproate","volume":"162","author":"Demyanenko","year":"2020","journal-title":"Brain Res. Bull."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115833_bib24","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/cmdc.202001011","article-title":"Oxa analogues of Nexturastat A demonstrate improved HDAC6 selectivity and superior antileukaemia activity","volume":"16","author":"Pflieger","year":"2021","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115833_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"FEBS J."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115833_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2174\/1389557516666160428115959","article-title":"Beyond the selective inhibition of histone deacetylase 6","volume":"16","author":"Rodrigues","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115833_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4020-6554-5_3","article-title":"The mitochondrial death pathway","volume":"615","author":"Chalah","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115833_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2023.115833_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107943","article-title":"The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy","volume":"230","author":"Basu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115833_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114082","article-title":"Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer","volume":"229","author":"Cui","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:50Z","timestamp":1759330850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"alternative-id":["S0223523423008000"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115833","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115833"}}